Bedrijfsoverzicht
ZeroStack Corp., operating under the ticker ZSTK, conducts pharmaceutical distribution activities primarily through its subsidiary, Phatebo GmbH, which focuses on the German market. The entity serves the Financial Services sector and specifically operates within the Asset Management industry, although its core operations involve the distribution of pharmaceutical goods and medical products to treat various health indications via Commercial, Wholesale, and Digital Assets segments. This publicly traded company maintains a relatively modest scale with a market capitalization of $12.59M and an annual revenue of $35.68M over the trailing twelve months. The company employs a workforce of 21 individuals to support its distribution network. These financial metrics indicate that ZeroStack Corp. operates as a small-cap entity, suggesting it is a niche player rather than a dominant force in the broader pharmaceutical or asset management markets.
Financiële gezondheid
The company reported a revenue of $35.68M for the trailing twelve months, yet this generated a net income of $-115,410,000, highlighting a significant structural cost burden that results in a complete lack of profitability despite substantial sales activity. The EBITDA stands at $-11,027,000, which further underscores the operational inefficiencies or high fixed costs associated with the distribution business model. Free cash flow is reported at $-5,176,000, indicating that the company is burning cash rather than generating liquidity, which severely limits its financial flexibility and reliance on external capital sources. Profitability is further eroded by a profit margin of 0.0%, while the gross margin sits at a thin 4.6% and the operating margin is a negative 54.8%, revealing that operating expenses consume the majority of gross profits. The balance sheet presents a leveraged position with total debt of $53.93M against cash holdings of $5.60M, resulting in a debt-to-equity ratio of 76.44. This disparity between liabilities and assets suggests a highly leveraged structure rather than a conservative one. Liquidity remains tight with a current ratio of 1.01, meaning the company holds just enough current assets to cover its current liabilities, leaving little buffer for short-term obligations. Return on Equity is severely depressed at -307.5% and Return on Assets is negative at -9.3%, metrics that reveal management is currently destroying shareholder value rather than generating returns on the capital deployed.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are both listed as N/A due to the company's negative earnings, which prevents the use of traditional earnings-based valuation multiples to assess value. Despite the lack of earnings-based multiples, the price-to-book ratio is 0.08, indicating that the market values the company at a fraction of its book value, reflecting deep skepticism regarding its tangible asset backing. Alternative valuation metrics such as the price-to-sales ratio of 0.35 and an EV/EBITDA of -5.53 suggest the stock is priced at a discount relative to its sales, though the negative EV/EBITDA confirms the company is not generating operating earnings. The stock has exhibited significant volatility over the last year, trading between a 52-week high of $47.00 and a 52-week low of $4.76. Based on the available data points, the current market price sits in a position that reflects the extreme variance between the high and low, though the specific percentage below the high cannot be calculated without the current share price, the range itself demonstrates a massive spread of 90.2% between the highest and lowest trading levels. The beta of 2.01 indicates that the stock's price volatility is twice that of the broader market, making it a high-risk instrument for investors seeking stability.
Growth & Income
Revenue growth over the last year stands at 22.3%, demonstrating an ability to expand sales volumes or capture market share, while earnings growth is N/A because the company remains in a loss-making state. Since there are no earnings to grow, the expansion of revenue does not yet translate into proportional profitability, implying that growth is currently occurring at the top line only. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders but instead retains all earnings, although the nature of these earnings is negative. Consequently, the company reinvests its limited resources back into operations rather than paying dividends, a strategy typical for small-cap firms attempting to stabilize losses. The overall growth and income profile is characterized by positive top-line expansion coupled with significant losses and a complete absence of dividend income.